We are proud to have Mats Magnusson of Pharmetheus as co-author to the publication ‘Exposure-Efficacy Analyses of Nintedanib in Patients with Chronic Fibrosing Interstitial Lung Disease’, accepted in the journal Respiratory Medicine. The article describes the pharmacometric analysis informing the recommended dose of nintedanib. The work was used to support the regulatory filing of nintedanib in patients with chronic fibrosing interstitial lung disease, and was performed in close collaboration with the pharmacometric team at Boehringer Ingelheim.
Read the publication here.
